Dual anticancer drug delivery of D-galactose-functionalized stimuli-responsive nanogels for targeted therapy of the liver hepatocellular carcinoma
Dual anticancer drug delivery of D-galactose-functionalized stimuli-responsive nanogels for targeted therapy of the liver hepatocellular carcinoma
نویسندگان: دکتر حسن نمازی , رویا صالحی قره ورن
کلمات کلیدی: β-Cyclodextrin, Fluorescent carbon quantum dot, Dual-responsive nanogels, Controlled co-drug release, D-galactose, Targeted human liver cancer treatment
نشریه: 11061 , 2022 , 167 , 2022
| نویسنده ثبت کننده مقاله |
دکتر حسن نمازی |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
مرکز تحقیقات ریز فناوری دارویی |
| کد مقاله |
78451 |
| عنوان فارسی مقاله |
Dual anticancer drug delivery of D-galactose-functionalized stimuli-responsive nanogels for targeted therapy of the liver hepatocellular carcinoma |
| عنوان لاتین مقاله |
Dual anticancer drug delivery of D-galactose-functionalized stimuli-responsive nanogels for targeted therapy of the liver hepatocellular carcinoma |
| ناشر |
3 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| In the current research work for the first time, we designed and fabricated a new double-responsive (pH and temperature) and photoluminescent nanogels capped with D-galactose (D-Gal) moieties (CQDs/β-CD/NIPAM@AA-Gal) in three steps and then evaluated its potential as a targeted drug carrier. The used common characterization techniques approved the success in fabrication of the CQDs/β-CD/NIPAM@AA-Gal nanogels. CQDs/β-CD/NIPAM@AA-Gal nanogels demonstrated homogeneous size distribution with an average hydrodynamic diameter of about 657 nm. About 47.8% and 72% of loading capacity respectively were observed respectively for methotrexate (MTX) and doxorubicin (DOX) anticancer drugs (MTX@DOX@CQDs/β-CD/NIPAM@AA-Gal). The controlled drug release ability of the MTX@DOX@CQDs/β-CD/NIPAM@AA-Gal was verified through a comparison of the drug release profiles at the simulated tumor and physiological conditions. In vitro cytotoxicity, 4′,6-diamidino-2-phenylindole (DAPI) staining, and cell cycle assays displayed the good biocompatibility of CQDs/β-CD/NIPAM@AA-Gal. Furthermore, fluorescent imaging approved its bioimaging potential. Overall summation of the achieved results proposes that the CQDs/β-CD/NIPAM@AA-Gal can be generally tested as a medical nanovehicle with a wide range of applicability potential for cancer cells monitoring and co-drug delivery. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| 10 P 2022 Poores_Salehi(European Polymer ).pdf | 1401/01/17 | 11628106 | دانلود |